In some cohorts, approximately 3% of people with clinically diagnosed FH are carriers of ABCG5/8 pathogenic variants [23,24,25], and including these genes in FH genetic testing panels increases yield and has precision medicine implications. This evidence concerns the gene ABCG5 and familial hyperaldosteronism.